Is cerebral glucose metabolism affected by chemotherapy in patients with Hodgkin's lymphoma?

Nuclear Medicine Communications

Volumn 34, Issue 1, 2013, Pages 57-63

  Chiaravalloti, Agostino ^a   Pagani, Marco ^b,d   Di Pietro, Barbara ^a   Danieli, Roberta ^a   Tavolozza, Mario ^a   Travascio, Laura ^a   Caracciolo, Cristiana R ^a   Simonetti, Giovanni ^a   Cantonetti, Maria ^a   Schillaci, Orazio ^a,c  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b INSTITUTE OF COGNITIVE SCIENCES AND TECHNOLOGIES   (Italy)

^c IRCCS NEUROMED   (Italy)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

ABVD; Chemobrain; Chemotherapy; Depression; Hodgkin's disease; Post traumatic stress disorder

Indexed keywords

BLEOMYCIN; DACARBAZINE; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; GLUCOSE; VINBLASTINE;

ADULT; ANGULAR GYRUS; ANTERIOR CINGULATE; ARTICLE; BRAIN METABOLISM; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DRUG UPTAKE; FEMALE; GLUCOSE METABOLISM; HODGKIN DISEASE; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; ORBITAL CORTEX; PREFRONTAL CORTEX;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL TRANSPORT; BLEOMYCIN; BRAIN; DACARBAZINE; DOXORUBICIN; FEMALE; FLUORODEOXYGLUCOSE F18; GLUCOSE; HODGKIN DISEASE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; TIME FACTORS; VINBLASTINE;

EID: 84870874325     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e32835aa7de     Document Type: Article

References (37)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60:277-300.
2. Bonadonna G, De Lena M, Monfardini S, Rossi A, Brambilla C, Uslenghi C, et al. Combination usage of adriamycin (NSC-123127) in malignant lymphomas. Cancer Chemother Rep 1975; 6:381-388.
3. Bonadonna G, Zucali R, Monfardini S, De Lena M, Uslenghi C. Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine and imidazole carboxamide versus MOPP. Cancer 1975; 36:252-259.
4. Chen Y, Jungsuwadee P, Vore M, Butterfield AD, St Clair DK. Collateral damage in cancer chemotherapy: oxidative stress in notargeted tissues. Mol Interv 2007; 7:147-156.
5. Canellos GP, Niedzwiecki D. Long-term follow-up of Hodgkin's disease trial. N Engl J Med 2002; 346:1417-1418.
6. Borchmann P, Andreas EA. The past: what we have learned in the last decade. Hematology Am Soc Hematol Educ Program 2010; 2010:101-107.
7. Domi{dotless}nguez AR, Marquez A, Guma J, Llanos M, Herrero J, De Las Nieves MA, et al. Treatment of stage I and II Hodgkin's lymphoma with ABVD chemotherapy: results after 7 years of a prospective study. Ann Oncol 2004; 15:1798-1804.
8. Enger A, Plütschow A, Eich HT, Lohri A, Dörken B, Borchmann P, et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med 2010; 363:640-652.
9. Owadally WS, Sydes MR, Radford JA, Hancock BW, Cullen MH, Stenning SP, Johnson PW. Initial dose intensity has limited impact on the outcome of ABVD chemotherapy for advanced Hodgkin lymphoma (HL): data from UKLG LY09 (ISRCTN97144519). Ann Oncol 2010; 21:568-573.
10. Boletizzz E, Mead GM. ABVD for Hodgkin's lymphoma: full-dose chemotherapy without dose reductions or growth factors. Ann Oncol 2007; 18:376-380.
11. Lopes MA, Meisel A, Dirnagl U, Carvalho FD, Bastos Mde L. Doxorubicin induces biphasic neurotoxicity to rat cortical neurons. Neurotoxicology 2008; 29:286-293.
12. Levin VA, Byrd D, Sikic BI, Etiz BB, Campbell J, Borcich JK, Davis RL. Central nervous toxicity and cerebrospinal fluid pharmacokinetics of intraventricularly administered bleomycin in beagles. Cancer Res 1985; 45:3810-3815.
13. Wedding U, Koch A, Röhrig B, Pientka L, Sauer H, Höffken K, et al. Depression and functional impairment independently contribute to decreased quality of life in cancer patients prior to chemotherapy. Acta Oncol 2008; 47:56-62.
14. Harter M, Reuter K, Aschenbrenner A, Schretzmann B, Marschner N, Hasenburg A, Weis J. Psychiatric disorders and associated factors in cancer: results of an interview study with patients in inpatient, rehabilitation and outpatient treatment. Eur J Cancer 2001; 37:1385-1393.
15. Reich M, Lesus A, Perdrizet-Chevallier C. Depression, quality of life and breast cancer: a review of the literature. Breast Cancer Res Treat 2008; 110:9-17.
16. Hughes KC, Shin LM. Functional neuroimaging studies of post-traumatic stress disorder. Expert Rev Neurother 2011; 11:275-285.
17. Liberzon I, Taylor SF, Amdur R, Jung TD, Chamberlain KR, Minoshima S, et al. Brain activation in PTSD in response to trauma-related stimuli. Biol Psychiatry 1999; 45:817-826.
18. Savitz J, Drevets WC. Bipolar and major depressive disorder: neuroimaging the developmental-degenerative divide. Neurosci Biobehav 2009; 33: 699-771.
19. Positron emission tomography (PET)-adapted chemotherapy in advanced hodgkin lymphoma (HL) (HD0607). Available at: http://www.clinicaltrials. gov/ct2/show/NCT00795613. [Accessed 24 October 2011].
20. Varrone A, Asenbaum S, Vander T, Booij J, Nobili F, Na°gren K, et al. EANM procedure guidelines for PET brain imaging using [18F]FDG, version 2. Eur J Nucl Med Mol Imaging 2009; 36:2104-2110.
21. Lister TA, Crowther D, Sutcliffe SB, Glatstein E, Canellos GP, Young RC, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989; 7:1630-1636.
22. Gallamini A, Fiore F, Sorasio R, Meignan M. Interim positron emission tomography scan in Hodgkin lymphoma: definitions, interpretation rules, and clinical validation. Leuk Lymphoma 2009; 50:1761-1764.
23. Gallamini A, Hutchings M, Rigacci L, Specht L, Merli F, Hansen M, et al. Early interim 2-[18F]fluoro-2-deoxy-D -glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 2007; 25:3746-3752.
24. Gallamini A, Rigacci L, Merli F, Nassi L, Bosi A, Capodanno I, et al. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. Hematologica 2006; 91:475-481.
25. Bennett CM, Wolford GL, Miller MB. The principled control of false 483 positives in neuroimaging. Soc Cogn Affect Neurosci 2009; 22: 2233-2239.
26. Wieneke MH, Dienst ER. Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer. Psychooncology 1995; 4:61-66.
27. Tannock JF, Ahles TA, Ganz PA, Van Dam FS. Cognitive impairment associated with chemotherapy for cancer: report of a workshop. J Clin Oncol 2004; 20:485-493.
28. George MS, Ketter AT, Post RM. Prefrontal cortex dysfunction in clinical depression. Depression 1994; 2:59-72.
29. Lesko LM, Massie MJ, Holland J. Oncology. In: Allan S, Fogel BS, Greenberg D, editors. Psychiatric care of the medical patient. New York: Oxford University Press; 1993. pp. 565-590.
30. McDaniel JS, Musselman DL, Porter MR, Reed DA, Nemeroff CB. Depression in patients with cancer. Arch Gen Psychiatry 1995; 52:82-99.
31. American Psychiatric Association (APA). Diagnostic and statistical manual of mental disorders. 4th ed Washington, DC: American Psychiatric Association (APA); 1994.
32. Mehnert A, Koch U. Prevalence of acute and post-traumatic stress disorder and comorbid mental disorders in breast cancer patients during primary cancer care: a prospective study. PsychoOncology 2007; 16:181-188.
33. Hakamata Y, Matsuoka Y, Inagaki M, Nagamine M, Hara E, Imoto S, et al. Structure of orbitofrontal cortex and its longitudinal course in cancer-related post-traumatic stress disorder. Neurosci Res 2007; 59:383-389.
34. Yamasue H, Kasai K, Iwanami A, Ohtani T, Yamada H, Abe O, et al. Voxelbased analysis of MRI reveals anterior cingulate gray-matter volume reduction in posttraumatic stress disorder due to terrorism. Proc Natl Acad Sci USA 2003; 100:9039-9043.
35. Bremner JD, Vermetten E, Vythilingam M, Afzal N, Schmahl C, Elzinga B, Charney DS. Neural correlates of the classic color and emotional stroop in women with abuse-related posttraumatic stress disorder. Biol Psychiatry 2004; 55:612-620.
36. Falleti MG, Sanfilippo A, Maruff P, Weih L, Phillips KA. The nature and severity of cognitive impairment associated with adjuvant chemotherapy qin women with breast cancer: a meta-analysis of the current literature. Brain Cogn 2005; 59:60-70.
37. Wefel JS, Lenzi R, Theriault RL, Davis RN, Meyers CA. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma. Cancer 2004; 100:2292-2299.